SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-150167
Filing Date
2022-05-13
Accepted
2022-05-13 16:32:23
Documents
13
Period of Report
2022-05-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d355542d8k.htm   iXBRL 8-K 25988
2 EX-99.1 d355542dex991.htm EX-99.1 13764
  Complete submission text file 0001193125-22-150167.txt   163311

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bbio-20220512.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20220512_lab.xml EX-101.LAB 17237
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20220512_pre.xml EX-101.PRE 10810
7 EXTRACTED XBRL INSTANCE DOCUMENT d355542d8k_htm.xml XML 3199
Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 22923327
SIC: 2834 Pharmaceutical Preparations